AMRX Q4 2024 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$731M+18.4% YoY

Gross Profit

$263M36.0% margin

Operating Income

$76M10.4% margin

Net Income

-$31M-4.3% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

$118M

Free Cash Flow

$95M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.5B

Stockholders' Equity

-$109M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$731M	$617M	+18.4%
Gross Profit	$263M	$225M	+16.6%
Operating Income	$76M	$14M	+434.0%
Net Income	-$31M	-$99M	+68.5%